Global Market Research Group

Albany, New York, Jan 17,2017 "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2016" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. Description- Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) Pipeline Review, H2 2016, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape. Get Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=903077 Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance. * Report Highlights Global Markets Direct'

"Retinitis Pigmentosa (Retinitis) Global Clinical Trials Review, H2, 2016" The Report covers current Market Trends, Analysis, Forecast, Review, Share, Size, Growth, Effect. Description- Summary GlobalData's clinical trial report, Retinitis Pigmentosa (Retinitis) Global Clinical Trials Review, H2, 2016" provides an overview of Retinitis Pigmentosa (Retinitis) clinical trials scenario. This report provides top line data relating to the clinical trials on Retinitis Pigmentosa (Retinitis). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical